Company profile: Xeris Biopharma
1.1 - Company Overview
Company description
- Provider of pharmaceutical therapies in endocrinology, neurology, and gastroenterology, including Gvoke and Ogluo ready-to-use glucagon injections for severe hypoglycemia; Keveyis, the first FDA-approved treatment for Primary Periodic Paralysis; Recorlev for endogenous Cushing's syndrome; and levothyroxine for hypothyroidism. Ogluo is marketed in the UK/EU under an exclusive agreement with Tetris Pharma.
Products and services
- Gvoke: A premixed, ready-to-use glucagon injection that treats severe hypoglycemia in adults and children with diabetes, offered in pediatric and adult dosing formats
- Recorlev: An endocrinology-focused treatment targeting endogenous Cushing's Syndrome, addressing a condition driven by prolonged exposure to high levels of cortisol
- Keveyis: The first FDA-approved treatment for Primary Periodic Paralysis, used to treat primary hyperkalemic and hypokalemic periodic paralysis and related diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Xeris Biopharma
Optinose
HQ: Norway
Website
- Description: Provider of nasal drug delivery technologies and combination drug/device therapies based on Bi-Directional Delivery, including Exhalation Delivery Systems for efficient deep nasal delivery. Offerings include XHANCE nasal spray for nasal polyps, ONZETRA Xsail for migraine treatment, and liquid and powder delivery devices using exhaled breath.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Optinose company profile →
Innocoll
HQ: United States
Website
- Description: Provider of targeted drug delivery solutions focused on biodegradable surgical implants and topically applied healthcare products, including XARACOLL, a resorbable collagen implant with bupivacaine for pain relief up to 24 hours after open inguinal hernia repair; POSIMIR, a single‑site bupivacaine injection providing relief up to 72 hours after arthroscopic subacromial decompression; the COLLARx collagen matrix platform; and CDMO services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Innocoll company profile →
Nanoleaf
HQ: Canada
Website
- Description: Provider of licensed, globally patented biotech technologies enabling proven pharmaceutical, nutraceutical, cosmetic, and functional beverage drug delivery formulations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nanoleaf company profile →
Nano Precision Medical
HQ: United States
Website
- Description: Provider of miniaturized subdermal implants using the NanoPortal membrane to deliver steady, long-term therapeutics for chronic diseases. Offerings include the NanoPortal Platform Technology; NPM-115 for chronic weight management and NPM-119 for type 2 diabetes, each designed to provide steady medication for up to six months; and Cortigent neurostimulation systems for artificial vision and muscle movement restoration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nano Precision Medical company profile →
Emisphere Technologies
HQ: United States
Website
- Description: Provider of proprietary Eligen Technology to develop new oral formulations of therapeutic agents, enhancing absorption of drugs typically administered via injection. A pharmaceutical company with multiple product candidates in clinical development and several in pre-clinical research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Emisphere Technologies company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Xeris Biopharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Xeris Biopharma
2.2 - Growth funds investing in similar companies to Xeris Biopharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Xeris Biopharma
4.2 - Public trading comparable groups for Xeris Biopharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →